Barbara Clothier

Mrs. Barbara Clothier


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2018 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
AMAnne C. Melzer
Anne C. Melzer
EPErika A. Pinsker
Erika A. Pinsker
BCBarbara Clothier
Barbara Clothier
SNSiamak Noorbaloochi
Siamak Noorbaloochi
DBDiana J. Burgess
Diana J. Burgess
SFSteven S. Fu
Steven S. Fu
Accurate smoking status is key for research purposes, but can be costly and difficult to measure. Within the Veteran’s Health Administration (VA), smoking status is recorded as part of routine care as “health factors” (HF)—fields that researchers can query through the electronic health record (EHR). Many researchers are interested in using these fields to track changes in smoking status over time, however the validity of this measure for assessing change is unknown. The primary goal of this project was to examine whether HFs can be used to accurately measure change in tobacco status over time, with secondary goals of assessing the optimum timeframe for assessment and variation in accuracy by site. Secondary analysis of the Veterans VICTORY study, a pragmatic smoking cessation randomized controlled trial conducted from 2009 to 2011. Eligible subjects were identified via the EHR using a past 90-day HF indicating current tobacco use (for example: “CURRENT SMOKER”, “CURRENTLY USES TOBACCO”). Participants were surveyed at 1 year to determine prolonged smoking abstinence. We identified HFs for tobacco status within +/− 120 days of the follow-up survey mailing date and recorded the temporally closest HF. Among subjects with both measures, we compared the two for agreement using kappa statistics and concordance. 1713 subjects (33%) had both follow-up survey and HF data, 1594 (31%) had only a survey response, 790 (15%) had only HF and 1026 (20%) had neither. For subjects with both measures, there was 90% concordance and moderate agreement (Kappa 0.48, 95%CI 0.41–0.55, Sensitivity 54.4, 95%CI 41.1–67.7, Specificity 94.3, 95%CI 87.5–100.0). We found high concordance but only moderate agreement by kappa statistics between HFs and survey data. The difference is likely accounted for by the natural history of quit attempts, in which patients cycle in and out of quit attempts. HFs appear to provide an accurate measure of population level quit behavior utilizing data collected in the course of clinical care.

1 January 2019 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
PHPatrick J. Hammett
Patrick J. Hammett
HLHarry A. Lando
Harry A. Lando
BTBrent C. Taylor
Brent C. Taylor
RWRachel Widome
Rachel Widome
DEDarin J. Erickson
Darin J. Erickson
SFSteven S. Fu
Steven S. Fu

1 March 2019 in Journal of Anxiety Disorders
Verified
Journal Article
Closed access
CRCraig S. Rosen
Craig S. Rosen
NBNancy C. Bernardy
Nancy C. Bernardy
KCKathleen M. Chard
Kathleen M. Chard
BCBarbara Clothier
Barbara Clothier
JCJoan M. Cook
Joan M. Cook
NSNina A. Sayer
Nina A. Sayer

3 January 2022 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
HHHildi J. Hagedorn
Hildi J. Hagedorn
AGAllison M. Gustavson
Allison M. Gustavson
PAPrincess E. Ackland
Princess E. Ackland
ABAnn Bangerter
Ann Bangerter
MBMark Bounthavong
Mark Bounthavong
AGAdam J. Gordon
Adam J. Gordon

9 April 2014 in BMC Public Health
Verified
Journal Article
Open access
PDF file
SFSteven S Fu
Steven S Fu
MRMichelle van Ryn
Michelle van Ryn
DBDiana J Burgess
Diana J Burgess
DNDavid Nelson
David Nelson
BCBarbara Clothier
Barbara Clothier
AJAnne M Joseph
Anne M Joseph
There is a high prevalence of smoking and high burden of tobacco-related diseases among low-income populations. Effective, evidenced-based smoking cessation treatments are available, but low-income smokers are less likely than higher-income smokers to use these treatments, especially the most comprehensive forms that include a combination of pharmacotherapy and intensive behavioral counseling. The primary objectives of this randomized controlled trial are to compare the effects of a proactive tobacco treatment intervention compared to usual care on population-level smoking abstinence rates and tobacco treatment utilization rates among a diverse population of low-income smokers, and to determine the cost-effectiveness of proactive tobacco treatment intervention. The proactive care intervention systematically offers low-income smokers free and easy access to evidence-based treatments and has two primary components: (1) proactive outreach to current smokers in the form of mailed invitation materials and telephone calls containing targeted health messages, and (2) facilitated access to free, comprehensive, evidence-based tobacco cessation treatments in the form of NRT and intensive, telephone-based behavioral counseling. The study aims to include a population-based sample (N = 2500) of adult smokers enrolled in the Minnesota Health Care Programs (MHCP), a state-funded health insurance plan for low-income persons. Baseline data is obtained from MHCP administrative databases and a participant survey that is conducted prior to randomization. Outcome data is collected from a follow-up survey conducted 12 months after randomization and MHCP administrative data. The primary outcome is six-month prolonged smoking abstinence at one year and is assessed at the population level. All randomized individuals are asked to complete the follow-up survey, regardless of whether they participated in tobacco treatment. Data analysis of the primary aims will follow intent-to-treat methodology. There is a critical need to increase access to effective tobacco dependence treatments. This randomized trial evaluates the effects of proactive outreach coupled with free NRT and telephone counseling on the population impact of tobacco dependence treatment. If proven to be effective and cost-effective, national dissemination of proactive treatment approaches would reduce tobacco-related morbidity, mortality, and health care costs for low income Americans. ClinicalTrials.gov: NCT01123967

1 March 2018 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
AMAnne C. Melzer
Anne C. Melzer
BCBarbara Clothier
Barbara Clothier
SJSandra J. Japuntich
Sandra J. Japuntich
SNSiamak Noorbaloochi
Siamak Noorbaloochi
PHPatrick Hammett
Patrick Hammett
SFSteven S. Fu
Steven S. Fu
Rationale: Adults with chronic lower respiratory disease differ in their barriers to smoking cessation but also suffer from tobacco-related health concerns, which may motivate quit attempts. Few studies have examined differences in tobacco treatment response between smokers with and without chronic lower respiratory disease. Objective: We examined the effectiveness of a proactive outreach program for cessation among smokers with and without chronic lower respiratory disease. Methods: Subgroup analysis of the Veterans Victory over Tobacco Study, a pragmatic randomized controlled trial that demonstrated the effectiveness of proactive outreach and the choice of tobacco treatments compared with usual care. Smokers identified via the electronic medical record were proactively offered phone-based counseling and care coordination to receive medication from their Veterans Affairs providers or in-person care. We compared the response among those with and without an International Classification of Diseases, 9th Revision diagnosis of a chronic lower respiratory disease (chronic obstructive pulmonary disease, chronic bronchitis, emphysema, asthma). We used stratification by propensity scores to adjust for imbalanced covariates between groups with and without chronic lower respiratory disease within each treatment arm, using complete case analysis accounting for the stratified sampling by site. Results: The study participants were predominantly older, white, male smokers. Overall, 19.6% had chronic lower respiratory disease. A total of 3,307 had outcome data with the following assignments to the intervention: proactive care: n = 1,272 without chronic lower respiratory disease, n = 301 with chronic lower respiratory disease; usual care: n = 1,387 without chronic lower respiratory disease, n = 347 with chronic lower respiratory disease. A total of 1,888 had both complete baseline and outcome data and were included in the primary analysis. In unadjusted analyses (n = 3,307), among individuals with chronic lower respiratory disease, 13.1% in the proactive group reported 6-month prolonged abstinence compared with 8.7% of those in the usual care group (odds ratio, 1.57; 95% confidence interval, 0.93–2.65). Among individuals without chronic lower respiratory disease, 13.1% quit in the proactive group compared with 11.0% in the usual care group (odds ratio, 1.22; 95% confidence interval, 0.95–1.55). In adjusted analyses (n = 1,888), the association between treatment arm and quit rate varied by the presence of chronic lower respiratory disease, with a stronger association between allocation to the proactive group and quit rate among those with chronic lower respiratory disease (odds ratio, 3.45; 95% confidence interval, 1.59–7.47) than those without chronic lower respiratory disease (odds ratio, 1.34; 95% confidence interval, 0.95–1.88; P for interaction with chronic lower respiratory disease = 0.03). Conclusions: Smokers with chronic lower respiratory disease may be more likely to respond to a proactive outreach intervention for tobacco cessation treatment than those without chronic lower respiratory disease. Clinical trial registered with www.clinicaltrials.gov (NCT 00608426).